TimXT personal page - To The Moon

TimXT

TimXT

No personal profile

63Follow

4Followers

2Topic

0Badge

2022-03-02

Hope for the better

Sorry, the original content has been removed

2021-08-25

$NIO Inc.(NIO)$is it time to sell?

2021-08-13

$BOUSTEAD PROJECTS LIMITED(AVM.SI)$ what happen ? Speechless

2021-08-03

Carefully see the cash flow of company. Definitely an opportunity as long as we invest in "solid" company

Sorry, the original content has been removed

2021-08-03

Good article. We need do our homework to check whether invest or not

When Will Stocks Drop? Watch Profit Margins (and Get Nervous)

2021-08-02

If there is a risk, there is an opportunity

3 Beaten-Down Growth Stocks to Buy Right Now

2021-08-02

Current civid situation will give opportunity for health sector

3 Beaten-Down Growth Stocks to Buy Right Now

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586676404731572","uuid":"3586676404731572","gmtCreate":1623582792957,"gmtModify":1629897646148,"name":"TimXT","pinyin":"timxt","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","hatId":"award-a6197a578fe7778e8d49a95ac425bcfc","hatName":"2024新年头像框-虎币抽奖","vip":1,"status":2,"fanSize":4,"headSize":63,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.07","exceedPercentage":"60.53%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.07","exceedPercentage":"93.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9033175710,"gmtCreate":1646231645640,"gmtModify":1676534106327,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586676404731572","idStr":"3586676404731572"},"themes":[],"htmlText":"Hope for the better","listText":"Hope for the better","text":"Hope for the better","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9033175710","repostId":"1167039770","repostType":2,"isVote":1,"tweetType":1,"viewCount":530,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837212814,"gmtCreate":1629892840338,"gmtModify":1676530164035,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586676404731572","idStr":"3586676404731572"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>is it time to sell?","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>is it time to sell?","text":"$NIO Inc.(NIO)$is it time to sell?","images":[{"img":"https://static.tigerbbs.com/b9725dc933b169340d1d76576561538f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/837212814","isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":894270866,"gmtCreate":1628833879455,"gmtModify":1676529869471,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586676404731572","idStr":"3586676404731572"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AVM.SI\">$BOUSTEAD PROJECTS LIMITED(AVM.SI)$</a> what happen ? Speechless&nbsp;","listText":"<a href=\"https://laohu8.com/S/AVM.SI\">$BOUSTEAD PROJECTS LIMITED(AVM.SI)$</a> what happen ? Speechless&nbsp;","text":"$BOUSTEAD PROJECTS LIMITED(AVM.SI)$ what happen ? Speechless","images":[{"img":"https://static.tigerbbs.com/48a896aa70fcaf777aa96432de4638b4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894270866","isVote":1,"tweetType":1,"viewCount":1149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":807069829,"gmtCreate":1627989325261,"gmtModify":1703499174959,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586676404731572","idStr":"3586676404731572"},"themes":[],"htmlText":"Carefully see the cash flow of company. Definitely an opportunity as long as we invest in \"solid\" company","listText":"Carefully see the cash flow of company. Definitely an opportunity as long as we invest in \"solid\" company","text":"Carefully see the cash flow of company. Definitely an opportunity as long as we invest in \"solid\" company","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807069829","repostId":"1199925585","repostType":4,"isVote":1,"tweetType":1,"viewCount":437,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804859753,"gmtCreate":1627950709672,"gmtModify":1703498355359,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586676404731572","idStr":"3586676404731572"},"themes":[],"htmlText":"Good article. We need do our homework to check whether invest or not","listText":"Good article. We need do our homework to check whether invest or not","text":"Good article. We need do our homework to check whether invest or not","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804859753","repostId":"1196763976","repostType":4,"repost":{"id":"1196763976","kind":"news","pubTimestamp":1627903466,"share":"https://ttm.financial/m/news/1196763976?lang=&edition=fundamental","pubTime":"2021-08-02 19:24","market":"us","language":"en","title":"When Will Stocks Drop? Watch Profit Margins (and Get Nervous)","url":"https://stock-news.laohu8.com/highlight/detail?id=1196763976","media":"Bloomberg","summary":"The evidence is mounting that companies are having a harder time passing off cost increases to their","content":"<blockquote>\n The evidence is mounting that companies are having a harder time passing off cost&nbsp;increases to their customers.\n</blockquote>\n<p>Want to know where the S&amp;P 500 Index may be headed after reaching another record high? Take a look at profit margins.</p>\n<p>Operating margin forecasts are a strong leading indicator of stock prices. A decline in such outlooks preceded routs in the S&amp;P 500 in 2011, 2015, 2018 and 2020. What’s concerning now is that analysts have stopped raising their forecasts, and if they begin to lower them, it's likely to lead to a dip in the broader market again. And it’s not like there’s a lot of room for further improvement in margins, defined as earnings before interest and taxes divided by sales. The consensus among analysts is that they will expand to 16.7% over the next 12 months, topping the previous record of 16.4% set in 2018.</p>\n<p>The relationship between S&amp;P 500 profitability and inflation indicators is murky at best, but recent spikes in the producer price index and a smaller increase in the consumer price index is enough to raise a caution flag for equity margin expansion potential for the next few quarters. At its peak in April, the PPI rose 9.5% from a year earlier, almost 3 standard deviations above its average over the past 30 years. (It rose 9.4% in June.) From 2010 to 2019, the median estimate of where operating margins would be 12 months into the future for S&amp;P 500 members were negatively correlated to changes in PPI. The current coefficient of minus 0.22 suggests gains in corporate profitability are likely to stall or even fall as producer prices continue to rise.</p>\n<p><b>Watch Those Margins</b></p>\n<p>Past dips in forecasted profit margins have lined up with pull-backs in equities.</p>\n<p><img src=\"https://static.tigerbbs.com/2dbda2c0b9394d518fdc8af7d693c8f3\" tg-width=\"644\" tg-height=\"283\" width=\"100%\" height=\"auto\">The difference between the PPI and CPI suggests companies are unable to pass cost increases on to consumers. The spread between the two fell to a record low of minus 5.3 percentage points in April, and is still strongly inverted at minus 4.1 percentage points. Over the last 30 years, the operating margin for the S&amp;P 500 narrowed 6.5 percentage points on average one year after the gap fell below minus 2 percentage points. Not only that, but in the year after the spread breached minus 2 percentage points, the S&amp;P fell 2.5% on average.</p>\n<p>Analysts are getting nervous. They have cut their margin estimates for a quarter of S&amp;P 500 members in the last three months. Their stocks were down 0.63%, compared with a gain of 2.20% for the index and a 3.30% increase for companies with rising margin forecasts. Slicing the index into quintiles based on changes in operating margin shows that companies with the largest declines had a median stock-price decline of 0.5%, versus a gain of 3.9% for those with the greatest expansion in consensus estimates.</p>\n<p>Industries with the most negative margin pressures are likely to be those that investors historically consider “defensive,” such as health care, utilities and consumer staples. Large companies involved in pharmaceuticals, biotechnology and life sciences, household and personal products, and utilities have historically fared worst when producer prices outrun consumer prices, and these are where margin forecasts gave dropped the most over the last three months. Margins forecasts continue to rise for the more cyclically-oriented segments of the equity market, with media, consumer services, transportation and oil and gas industries having the largest gains.</p>\n<p><b>Winners and Losers</b></p>\n<p>Cyclically-oriented sectors are relatively immune from broad profit margin compression.</p>\n<p><img src=\"https://static.tigerbbs.com/884366efc825eccec2878fcd4b3f0912\" tg-width=\"640\" tg-height=\"533\" width=\"100%\" height=\"auto\">Though consensus expectations imply smooth sailing, companies are set up for a more challenging margin outlook as revenue growth rates likely fade, but inflation pressures remain relatively high given persistent uncertainty in the supply chain. Against this backdrop, currently selective industry margin weaknesses may start to spread to more industries, resulting in degradation of margin forecasts for the index at large. Given these estimates are a strong strong leading indicator of stock-price direction, margin trends may be a critical risk to the equity market in the months ahead.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>When Will Stocks Drop? Watch Profit Margins (and Get Nervous)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhen Will Stocks Drop? Watch Profit Margins (and Get Nervous)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 19:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The evidence is mounting that companies are having a harder time passing off cost increases to their customers.\n\nWant to know where the S&P 500 Index may be headed after reaching another record high? ...</p>\n\n<a href=\"https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","SPY":"标普500ETF"},"source_url":"https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196763976","content_text":"The evidence is mounting that companies are having a harder time passing off cost increases to their customers.\n\nWant to know where the S&P 500 Index may be headed after reaching another record high? Take a look at profit margins.\nOperating margin forecasts are a strong leading indicator of stock prices. A decline in such outlooks preceded routs in the S&P 500 in 2011, 2015, 2018 and 2020. What’s concerning now is that analysts have stopped raising their forecasts, and if they begin to lower them, it's likely to lead to a dip in the broader market again. And it’s not like there’s a lot of room for further improvement in margins, defined as earnings before interest and taxes divided by sales. The consensus among analysts is that they will expand to 16.7% over the next 12 months, topping the previous record of 16.4% set in 2018.\nThe relationship between S&P 500 profitability and inflation indicators is murky at best, but recent spikes in the producer price index and a smaller increase in the consumer price index is enough to raise a caution flag for equity margin expansion potential for the next few quarters. At its peak in April, the PPI rose 9.5% from a year earlier, almost 3 standard deviations above its average over the past 30 years. (It rose 9.4% in June.) From 2010 to 2019, the median estimate of where operating margins would be 12 months into the future for S&P 500 members were negatively correlated to changes in PPI. The current coefficient of minus 0.22 suggests gains in corporate profitability are likely to stall or even fall as producer prices continue to rise.\nWatch Those Margins\nPast dips in forecasted profit margins have lined up with pull-backs in equities.\nThe difference between the PPI and CPI suggests companies are unable to pass cost increases on to consumers. The spread between the two fell to a record low of minus 5.3 percentage points in April, and is still strongly inverted at minus 4.1 percentage points. Over the last 30 years, the operating margin for the S&P 500 narrowed 6.5 percentage points on average one year after the gap fell below minus 2 percentage points. Not only that, but in the year after the spread breached minus 2 percentage points, the S&P fell 2.5% on average.\nAnalysts are getting nervous. They have cut their margin estimates for a quarter of S&P 500 members in the last three months. Their stocks were down 0.63%, compared with a gain of 2.20% for the index and a 3.30% increase for companies with rising margin forecasts. Slicing the index into quintiles based on changes in operating margin shows that companies with the largest declines had a median stock-price decline of 0.5%, versus a gain of 3.9% for those with the greatest expansion in consensus estimates.\nIndustries with the most negative margin pressures are likely to be those that investors historically consider “defensive,” such as health care, utilities and consumer staples. Large companies involved in pharmaceuticals, biotechnology and life sciences, household and personal products, and utilities have historically fared worst when producer prices outrun consumer prices, and these are where margin forecasts gave dropped the most over the last three months. Margins forecasts continue to rise for the more cyclically-oriented segments of the equity market, with media, consumer services, transportation and oil and gas industries having the largest gains.\nWinners and Losers\nCyclically-oriented sectors are relatively immune from broad profit margin compression.\nThough consensus expectations imply smooth sailing, companies are set up for a more challenging margin outlook as revenue growth rates likely fade, but inflation pressures remain relatively high given persistent uncertainty in the supply chain. Against this backdrop, currently selective industry margin weaknesses may start to spread to more industries, resulting in degradation of margin forecasts for the index at large. Given these estimates are a strong strong leading indicator of stock-price direction, margin trends may be a critical risk to the equity market in the months ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805759967,"gmtCreate":1627908887059,"gmtModify":1703497635229,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586676404731572","idStr":"3586676404731572"},"themes":[],"htmlText":"If there is a risk, there is an opportunity&nbsp;","listText":"If there is a risk, there is an opportunity&nbsp;","text":"If there is a risk, there is an opportunity","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805759967","repostId":"2156864192","repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://ttm.financial/m/news/2156864192?lang=&edition=fundamental","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"tweetType":1,"viewCount":744,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805750398,"gmtCreate":1627908849214,"gmtModify":1703497634066,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586676404731572","idStr":"3586676404731572"},"themes":[],"htmlText":"Current civid situation&nbsp; will give opportunity for health sector&nbsp;","listText":"Current civid situation&nbsp; will give opportunity for health sector&nbsp;","text":"Current civid situation will give opportunity for health sector","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805750398","repostId":"2156864192","repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://ttm.financial/m/news/2156864192?lang=&edition=fundamental","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"tweetType":1,"viewCount":818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9033175710,"gmtCreate":1646231645640,"gmtModify":1676534106327,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3586676404731572","authorIdStr":"3586676404731572"},"themes":[],"htmlText":"Hope for the better","listText":"Hope for the better","text":"Hope for the better","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9033175710","repostId":"1167039770","repostType":2,"repost":{"id":"1167039770","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1646231563,"share":"https://ttm.financial/m/news/1167039770?lang=&edition=fundamental","pubTime":"2022-03-02 22:32","market":"us","language":"en","title":"Dow rebounds Wednesday as investors shake off intensifying Russia-Ukraine conflict, spiking oil","url":"https://stock-news.laohu8.com/highlight/detail?id=1167039770","media":"Tiger Newspress","summary":"Stocks rose on Wednesday despite a continued surge in oil prices surged amid the intensifying confli","content":"<html><head></head><body><p>Stocks rose on Wednesday despite a continued surge in oil prices surged amid the intensifying conflict between Russia and Ukraine.</p><p>The Dow Jones Industrial Average gained 228 points, or 0.7%. The S&amp;P 500 and Nasdaq Composite added about 0.4% and 0.2%, respectively.</p><p>Oil and gas stocks and chip stocks rose, while silver and gold stocks fell.</p><p>Salesforce rose more than 3%, its fourth quarter revenue increased by 26% year-on-year, and the Q1 and full year revenue guidelines of fiscal 2023 exceeded market expectations.</p><p>Nordstrom rose more than 26%, and its fourth quarter profit soared fivefold to $200 million by the end of January.</p><p>Sofi rose more than 15%, and its new members increased by 39% to 523000 in the fourth quarter. It is expected that the adjusted revenue growth in the first quarter will be as high as 55%.</p><p>Corporate news helped push the market higher. Shares of Ford popped 4.6% in after the automaker announced it would split its electric vehicle and legacy production businesses into two separate units.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow rebounds Wednesday as investors shake off intensifying Russia-Ukraine conflict, spiking oil</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow rebounds Wednesday as investors shake off intensifying Russia-Ukraine conflict, spiking oil\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-02 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Stocks rose on Wednesday despite a continued surge in oil prices surged amid the intensifying conflict between Russia and Ukraine.</p><p>The Dow Jones Industrial Average gained 228 points, or 0.7%. The S&amp;P 500 and Nasdaq Composite added about 0.4% and 0.2%, respectively.</p><p>Oil and gas stocks and chip stocks rose, while silver and gold stocks fell.</p><p>Salesforce rose more than 3%, its fourth quarter revenue increased by 26% year-on-year, and the Q1 and full year revenue guidelines of fiscal 2023 exceeded market expectations.</p><p>Nordstrom rose more than 26%, and its fourth quarter profit soared fivefold to $200 million by the end of January.</p><p>Sofi rose more than 15%, and its new members increased by 39% to 523000 in the fourth quarter. It is expected that the adjusted revenue growth in the first quarter will be as high as 55%.</p><p>Corporate news helped push the market higher. Shares of Ford popped 4.6% in after the automaker announced it would split its electric vehicle and legacy production businesses into two separate units.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167039770","content_text":"Stocks rose on Wednesday despite a continued surge in oil prices surged amid the intensifying conflict between Russia and Ukraine.The Dow Jones Industrial Average gained 228 points, or 0.7%. The S&P 500 and Nasdaq Composite added about 0.4% and 0.2%, respectively.Oil and gas stocks and chip stocks rose, while silver and gold stocks fell.Salesforce rose more than 3%, its fourth quarter revenue increased by 26% year-on-year, and the Q1 and full year revenue guidelines of fiscal 2023 exceeded market expectations.Nordstrom rose more than 26%, and its fourth quarter profit soared fivefold to $200 million by the end of January.Sofi rose more than 15%, and its new members increased by 39% to 523000 in the fourth quarter. It is expected that the adjusted revenue growth in the first quarter will be as high as 55%.Corporate news helped push the market higher. Shares of Ford popped 4.6% in after the automaker announced it would split its electric vehicle and legacy production businesses into two separate units.","news_type":1},"isVote":1,"tweetType":1,"viewCount":530,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804859753,"gmtCreate":1627950709672,"gmtModify":1703498355359,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3586676404731572","authorIdStr":"3586676404731572"},"themes":[],"htmlText":"Good article. We need do our homework to check whether invest or not","listText":"Good article. We need do our homework to check whether invest or not","text":"Good article. We need do our homework to check whether invest or not","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804859753","repostId":"1196763976","repostType":4,"repost":{"id":"1196763976","kind":"news","pubTimestamp":1627903466,"share":"https://ttm.financial/m/news/1196763976?lang=&edition=fundamental","pubTime":"2021-08-02 19:24","market":"us","language":"en","title":"When Will Stocks Drop? Watch Profit Margins (and Get Nervous)","url":"https://stock-news.laohu8.com/highlight/detail?id=1196763976","media":"Bloomberg","summary":"The evidence is mounting that companies are having a harder time passing off cost increases to their","content":"<blockquote>\n The evidence is mounting that companies are having a harder time passing off cost&nbsp;increases to their customers.\n</blockquote>\n<p>Want to know where the S&amp;P 500 Index may be headed after reaching another record high? Take a look at profit margins.</p>\n<p>Operating margin forecasts are a strong leading indicator of stock prices. A decline in such outlooks preceded routs in the S&amp;P 500 in 2011, 2015, 2018 and 2020. What’s concerning now is that analysts have stopped raising their forecasts, and if they begin to lower them, it's likely to lead to a dip in the broader market again. And it’s not like there’s a lot of room for further improvement in margins, defined as earnings before interest and taxes divided by sales. The consensus among analysts is that they will expand to 16.7% over the next 12 months, topping the previous record of 16.4% set in 2018.</p>\n<p>The relationship between S&amp;P 500 profitability and inflation indicators is murky at best, but recent spikes in the producer price index and a smaller increase in the consumer price index is enough to raise a caution flag for equity margin expansion potential for the next few quarters. At its peak in April, the PPI rose 9.5% from a year earlier, almost 3 standard deviations above its average over the past 30 years. (It rose 9.4% in June.) From 2010 to 2019, the median estimate of where operating margins would be 12 months into the future for S&amp;P 500 members were negatively correlated to changes in PPI. The current coefficient of minus 0.22 suggests gains in corporate profitability are likely to stall or even fall as producer prices continue to rise.</p>\n<p><b>Watch Those Margins</b></p>\n<p>Past dips in forecasted profit margins have lined up with pull-backs in equities.</p>\n<p><img src=\"https://static.tigerbbs.com/2dbda2c0b9394d518fdc8af7d693c8f3\" tg-width=\"644\" tg-height=\"283\" width=\"100%\" height=\"auto\">The difference between the PPI and CPI suggests companies are unable to pass cost increases on to consumers. The spread between the two fell to a record low of minus 5.3 percentage points in April, and is still strongly inverted at minus 4.1 percentage points. Over the last 30 years, the operating margin for the S&amp;P 500 narrowed 6.5 percentage points on average one year after the gap fell below minus 2 percentage points. Not only that, but in the year after the spread breached minus 2 percentage points, the S&amp;P fell 2.5% on average.</p>\n<p>Analysts are getting nervous. They have cut their margin estimates for a quarter of S&amp;P 500 members in the last three months. Their stocks were down 0.63%, compared with a gain of 2.20% for the index and a 3.30% increase for companies with rising margin forecasts. Slicing the index into quintiles based on changes in operating margin shows that companies with the largest declines had a median stock-price decline of 0.5%, versus a gain of 3.9% for those with the greatest expansion in consensus estimates.</p>\n<p>Industries with the most negative margin pressures are likely to be those that investors historically consider “defensive,” such as health care, utilities and consumer staples. Large companies involved in pharmaceuticals, biotechnology and life sciences, household and personal products, and utilities have historically fared worst when producer prices outrun consumer prices, and these are where margin forecasts gave dropped the most over the last three months. Margins forecasts continue to rise for the more cyclically-oriented segments of the equity market, with media, consumer services, transportation and oil and gas industries having the largest gains.</p>\n<p><b>Winners and Losers</b></p>\n<p>Cyclically-oriented sectors are relatively immune from broad profit margin compression.</p>\n<p><img src=\"https://static.tigerbbs.com/884366efc825eccec2878fcd4b3f0912\" tg-width=\"640\" tg-height=\"533\" width=\"100%\" height=\"auto\">Though consensus expectations imply smooth sailing, companies are set up for a more challenging margin outlook as revenue growth rates likely fade, but inflation pressures remain relatively high given persistent uncertainty in the supply chain. Against this backdrop, currently selective industry margin weaknesses may start to spread to more industries, resulting in degradation of margin forecasts for the index at large. Given these estimates are a strong strong leading indicator of stock-price direction, margin trends may be a critical risk to the equity market in the months ahead.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>When Will Stocks Drop? Watch Profit Margins (and Get Nervous)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhen Will Stocks Drop? Watch Profit Margins (and Get Nervous)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 19:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The evidence is mounting that companies are having a harder time passing off cost increases to their customers.\n\nWant to know where the S&P 500 Index may be headed after reaching another record high? ...</p>\n\n<a href=\"https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","SPY":"标普500ETF"},"source_url":"https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196763976","content_text":"The evidence is mounting that companies are having a harder time passing off cost increases to their customers.\n\nWant to know where the S&P 500 Index may be headed after reaching another record high? Take a look at profit margins.\nOperating margin forecasts are a strong leading indicator of stock prices. A decline in such outlooks preceded routs in the S&P 500 in 2011, 2015, 2018 and 2020. What’s concerning now is that analysts have stopped raising their forecasts, and if they begin to lower them, it's likely to lead to a dip in the broader market again. And it’s not like there’s a lot of room for further improvement in margins, defined as earnings before interest and taxes divided by sales. The consensus among analysts is that they will expand to 16.7% over the next 12 months, topping the previous record of 16.4% set in 2018.\nThe relationship between S&P 500 profitability and inflation indicators is murky at best, but recent spikes in the producer price index and a smaller increase in the consumer price index is enough to raise a caution flag for equity margin expansion potential for the next few quarters. At its peak in April, the PPI rose 9.5% from a year earlier, almost 3 standard deviations above its average over the past 30 years. (It rose 9.4% in June.) From 2010 to 2019, the median estimate of where operating margins would be 12 months into the future for S&P 500 members were negatively correlated to changes in PPI. The current coefficient of minus 0.22 suggests gains in corporate profitability are likely to stall or even fall as producer prices continue to rise.\nWatch Those Margins\nPast dips in forecasted profit margins have lined up with pull-backs in equities.\nThe difference between the PPI and CPI suggests companies are unable to pass cost increases on to consumers. The spread between the two fell to a record low of minus 5.3 percentage points in April, and is still strongly inverted at minus 4.1 percentage points. Over the last 30 years, the operating margin for the S&P 500 narrowed 6.5 percentage points on average one year after the gap fell below minus 2 percentage points. Not only that, but in the year after the spread breached minus 2 percentage points, the S&P fell 2.5% on average.\nAnalysts are getting nervous. They have cut their margin estimates for a quarter of S&P 500 members in the last three months. Their stocks were down 0.63%, compared with a gain of 2.20% for the index and a 3.30% increase for companies with rising margin forecasts. Slicing the index into quintiles based on changes in operating margin shows that companies with the largest declines had a median stock-price decline of 0.5%, versus a gain of 3.9% for those with the greatest expansion in consensus estimates.\nIndustries with the most negative margin pressures are likely to be those that investors historically consider “defensive,” such as health care, utilities and consumer staples. Large companies involved in pharmaceuticals, biotechnology and life sciences, household and personal products, and utilities have historically fared worst when producer prices outrun consumer prices, and these are where margin forecasts gave dropped the most over the last three months. Margins forecasts continue to rise for the more cyclically-oriented segments of the equity market, with media, consumer services, transportation and oil and gas industries having the largest gains.\nWinners and Losers\nCyclically-oriented sectors are relatively immune from broad profit margin compression.\nThough consensus expectations imply smooth sailing, companies are set up for a more challenging margin outlook as revenue growth rates likely fade, but inflation pressures remain relatively high given persistent uncertainty in the supply chain. Against this backdrop, currently selective industry margin weaknesses may start to spread to more industries, resulting in degradation of margin forecasts for the index at large. Given these estimates are a strong strong leading indicator of stock-price direction, margin trends may be a critical risk to the equity market in the months ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894270866,"gmtCreate":1628833879455,"gmtModify":1676529869471,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3586676404731572","authorIdStr":"3586676404731572"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AVM.SI\">$BOUSTEAD PROJECTS LIMITED(AVM.SI)$</a> what happen ? Speechless&nbsp;","listText":"<a href=\"https://laohu8.com/S/AVM.SI\">$BOUSTEAD PROJECTS LIMITED(AVM.SI)$</a> what happen ? Speechless&nbsp;","text":"$BOUSTEAD PROJECTS LIMITED(AVM.SI)$ what happen ? Speechless","images":[{"img":"https://static.tigerbbs.com/48a896aa70fcaf777aa96432de4638b4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894270866","isVote":1,"tweetType":1,"viewCount":1149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":837212814,"gmtCreate":1629892840338,"gmtModify":1676530164035,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3586676404731572","authorIdStr":"3586676404731572"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>is it time to sell?","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>is it time to sell?","text":"$NIO Inc.(NIO)$is it time to sell?","images":[{"img":"https://static.tigerbbs.com/b9725dc933b169340d1d76576561538f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/837212814","isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":807069829,"gmtCreate":1627989325261,"gmtModify":1703499174959,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3586676404731572","authorIdStr":"3586676404731572"},"themes":[],"htmlText":"Carefully see the cash flow of company. Definitely an opportunity as long as we invest in \"solid\" company","listText":"Carefully see the cash flow of company. Definitely an opportunity as long as we invest in \"solid\" company","text":"Carefully see the cash flow of company. Definitely an opportunity as long as we invest in \"solid\" company","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807069829","repostId":"1199925585","repostType":4,"isVote":1,"tweetType":1,"viewCount":437,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805759967,"gmtCreate":1627908887059,"gmtModify":1703497635229,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3586676404731572","authorIdStr":"3586676404731572"},"themes":[],"htmlText":"If there is a risk, there is an opportunity&nbsp;","listText":"If there is a risk, there is an opportunity&nbsp;","text":"If there is a risk, there is an opportunity","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805759967","repostId":"2156864192","repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://ttm.financial/m/news/2156864192?lang=&edition=fundamental","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"tweetType":1,"viewCount":744,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805750398,"gmtCreate":1627908849214,"gmtModify":1703497634066,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3586676404731572","authorIdStr":"3586676404731572"},"themes":[],"htmlText":"Current civid situation&nbsp; will give opportunity for health sector&nbsp;","listText":"Current civid situation&nbsp; will give opportunity for health sector&nbsp;","text":"Current civid situation will give opportunity for health sector","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805750398","repostId":"2156864192","repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://ttm.financial/m/news/2156864192?lang=&edition=fundamental","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"tweetType":1,"viewCount":818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}